In the randomized, double-blind, phase 3 study, experts explored treatment with neoadjuvant pembrolizumab (Keytruda) plus chemotherapy, followed by adjuvant pembrolizumab, in patients aged 18 years ...

The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with ...

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE ...

Oncologists never know which patients with dire prognoses will be among the rare, but real responders. The few who defy all ...

The imaging agent Gleolan is only approved for glioma surgery, so the current trial could lead to a new indication. In this ...

Kintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors (the ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

"Exelixis and MSD to trial cancer therapies together in clinical collaboration" was originally created and published by ...

Researchers have discovered that combining immunotherapy and chemotherapy can overcome treatment resistance in a subset of ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYNOTE-689 trial ...

Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...